All trading involves risk. Contracts for Difference (CFDs) are complex instruments and may not be suitable for all investors. Please refer to Risk Disclosure and Risk Fact Sheet on Capital.com/en-sg.
Open platformOpen platform

MaxCyte looks to acquire Akron Bio to expand cell therapy manufacturing; Q3 revenue rises

By Reuters News


Overview

  • US cell engineering platform's Q3 revenue rose 49% yr/yr

  • Q3 adjusted EBITDA loss narrowed and beat analyst expectations

  • Company announced proposed acquisition of Akron Bio to expand cell therapy manufacturing


Outlook

  • MaxCyte raises 2026 revenue guidance to at least $34.5 mln

  • Company expects 2026 core revenue of about $28 mln

  • Company sees 2026 SPL Program-related revenue of at least $6.5 mln


Result Drivers

  • CORE BUSINESS GROWTH - Co said core revenue rose 27% yr/yr, driven by increased instrument and consumables sales

  • SPL PROGRAM REVENUE - SPL Program-related revenue increased, supported by higher milestone payments and royalties

  • EXPENSE MANAGEMENT - Co reduced operating expenses yr/yr, contributing to a narrower net loss


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Net Loss

$4.8 mln

Q3 Adjusted EBITDA

Beat

-$5.1 mln

-$7.99 mln (4 Analysts)

Cash & Investments as of Sept 30

$132.7 mln

Q3 Gross Profit

$8.5 mln

Q3 Operating Expenses

$14.5 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for MaxCyte Inc is $4.50, about 246.2% above its November 9 closing price of $1.30


Reuters Recommended Reads

  • Nov 9 - Senseonics Q3 revenue jumps, raises 2026 outlook

  • Nov 9 - Editas Medicine Q3 net loss narrows

  • Nov 9 - US FDA approves Bayer's blood thinner to prevent repeat strokes


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.